| 6.59 -0.18 (-2.66%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.8  |
1-year : | 9.48 |
| Resists | First : | 7.53 |
Second : | 8.11 |
| Pivot price | 7.33 |
|||
| Supports | First : | 6.59 |
Second : | 5.48 |
| MAs | MA(5) : | 6.81 |
MA(20) : | 7.47 |
| MA(100) : | 7.3  |
MA(250) : | 10.31 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 7.8 | D(3) : | 6.6 |
| RSI | RSI(14): 24.2 |
|||
| 52-week | High : | 19.35 | Low : | 5.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KALA ] has closed above bottom band by 7.4%. Bollinger Bands are 11.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.87 - 6.94 | 6.94 - 6.98 |
| Low: | 6.45 - 6.54 | 6.54 - 6.59 |
| Close: | 6.49 - 6.63 | 6.63 - 6.71 |
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Thu, 18 Apr 2024
What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)? - Yahoo Movies UK
Thu, 28 Mar 2024
KALA Stock Quote Price and Forecast - CNN
Tue, 29 Aug 2023
Acute Ocular Pain Market to Witness Positive Growth by 2032, Examines DelveInsight | Key Players - Formosa, Surface ... - GlobeNewswire
Wed, 02 Aug 2023
Kala Pharmaceuticals Announces Name Change to KALA BIO - GlobeNewswire
Thu, 13 Apr 2023
Kala's KPI-012 secures FDA Fast Track status to treat PCED - Pharmaceutical Technology
Fri, 30 Dec 2022
Kala Pharmaceuticals announces FDA acceptance of IND application for KPI-012 for treatment of PCED - Ophthalmology Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 17.9 (%) |
| Held by Institutions | 22.7 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -17.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.3 % |
| Return on Equity (ttm) | -318.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.38 |
| PEG Ratio | -0.1 |
| Price to Book value | 2.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|